請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4524完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 周崇熙,王宏文 | |
| dc.contributor.author | Hsiao-Fu Chueh | en |
| dc.contributor.author | 闕筱芙 | zh_TW |
| dc.date.accessioned | 2021-05-14T17:42:59Z | - |
| dc.date.available | 2018-08-16 | |
| dc.date.available | 2021-05-14T17:42:59Z | - |
| dc.date.copyright | 2015-08-16 | |
| dc.date.issued | 2015 | |
| dc.date.submitted | 2015-08-12 | |
| dc.identifier.citation | [1] 王明升(2010)。標準化實驗動物房舍設施之規劃。蔡倉吾（主編），實驗動物管理與使用指南第三版。行政院農業委員會，台北市。
[2] 王斌永(2012)。雞場管理決策支援系統。博士論文。國立中興大學動物科學系所，台中市。 [3] 王斌永、阮喜文(2008)。台灣蛋雞場經營管理知識庫之建立。畜產研究季刊，42，13-18。 [4] 余祁暐(2013)。臺灣動物用疫苗產業發展現況。農業生技產業季刊，34，14-20。 [5] 阮喜文(1997)。禽畜生產的成本結構。阮喜文，畜產經營學修訂版。中興大學教務處出版組，台中市。 [6] 周芳君(2011)。從全球疫苗產業趨勢探討我國預防接種的政策發展。碩士論文。國立政治大學科技管理研究所，台北市。 [7] 李宜映、林海珍(2009)。以情境分析建構台灣農業未來願景。台灣經濟研究月刊，12，41-47。 [8] 林仁喜(2006)。蛋雞產業經濟效益分析。碩士論文。國立雲林科技大學財務金融系，雲林縣。 [9] 林海明(2007)。生物製劑先導工廠建築規劃之研究。碩士論文。中華大學營建管理學系，新竹市。 [10] 林漢昌(2007)。實驗動物室空調設計實例探討與環控量測數據之比較研究。碩士論文。國立台北科技大學能源與冷凍空調工程系，台北市。 [11] 林亞歆(2014)。台灣農業生技 巧實力創新經濟 創新經濟。取自: http://www.gbimonthly.com/v10_2014/v10coverstory_2014_00.html [12] 社團法人國家生技醫療產業策進會(2007)。台灣生技醫療產業政策總體檢。取自: http://www.ibmi.org.tw/bioindustryforum/2015 [13] 胡勇誌(2013)。新型流感 H5N1 疫苗的發展與挑戰。感染控制雜誌，23，41-45。 [14] 高俊傑(1997)。種雞場經營效益診斷支援系統。碩士論文。國立中興大學動物科學系所，台中市。 [15] 張四明(2001)。成本效益分析在政府決策上的應用與限制。行政暨政策學報，3，45-80。 [16] 莊雅惠(2008)。生物醫療廢棄物處理技術對環境之衝擊暨成本效益分析。碩士論文)。國立臺北大學自然資源與環境管理研究所，台北市。 [17] 許育菁(2005)。蛋雞場管理模式比較與對雞蛋生產表現之影響。國立臺灣海洋大學食品科學系碩士論文。國立臺灣海洋大學食品科學系，基隆市。 [18] 許振忠(2009)。蛋雞場生物安全良好作業規範。台北市：台北市財團法人中央畜產會。 [19] 郭昱瑩(2005)。決策幫手：成本效益分析之概念與實務。T&D 飛訊，1-4。 [20] 陳政忻(2007)。專訪高生製藥股份有限公司。農業生技產業季刊，15，75-79。 [21] 陳政忻(2008)。2007年全球動物保健市場現況。農業生技產業季刊，15，1-5。 [22] 陳添寶(2005)。我國動物用藥品產業經營策略之研究—中國化學製藥公司為例。碩士論文。南台科技大學高階主管企管碩士班，台南市。 [23] 彭克仲(2009)。成本效益分析應用於農場經營與規劃。興大農業期刊，70，22-27。 [24] 黃元品、張婉純、王金和(2005)。家禽傳染性支氣管炎台灣一型減毒疫苗之評估。臺灣獸醫學雜誌，31，148-154。 [25] 黃元品、張婉純、王金和(2006)。家禽傳染性支氣管炎台灣二型減毒疫苗之評估。臺灣獸醫學雜誌，32，123-128。 [26] 黃國鐘(2004)。成本效益分析簡評。律師雜誌，299，49-67。 [27] 黃惠珣、黃婉婷、張志熙、李佳琳、劉定萍(2014)。2013-2014年流感季流感疫苗保護效力評估初探。疫情報導，30，428-433。 [28] 葉俊沐(2010)。台灣動物用藥品優良製造管理。農業生技產業季刊，22，11-14。 [29] 詹東榮(2008)。動物用生物藥品管理現況與展望。農業生技產業季刊，15，6-13。 [30] 劉志春(2013)。雞的飼養與管理。載於劉志春，雞類飼養與繁殖。五洲出版社，新北市。 [31] 劉瑞珍、劉振發、張致維、黎煥耀、戴謙、陳立人(2007)。分子牧場之應用與開發I-以母雞為生物工廠生產抗腸病毒71型IgY抗體。農業生技產業季刊，34-41。 [32] 蔡倉吾(2010)。實驗動物管理與使用指南。行政院農業委員會，台北市。 [33] 謝佩娟(2011)。臺北市信義區學齡前幼兒家長對其子女接種流感疫苗的意願因素分析(國立臺灣大學公共衛生碩士學位學程碩士論文)。國立臺灣大學，台北市。 [34] Adamiak, G.. (2006). Methods for the Economic Evaluation of Health Care Programmes. Journal of Epidemiology and Community Health 60, 822-823. [35] Animal and Plant Health Inspection Service. (2011). Veterinary Services Memorandum 800.65. United States Department of Agriculture, the United States of America. [36] Baguelin M., Hoek A.J., Jit M., Flasche S., White P.J., Edmunds WJ.. (2010). Vaccination against Pandemic Influenza A/H1N1v in England: A Real-Time Economic Evaluation. Vaccine 28, 2370-2384. [37] Booth, W.C., Colomb, G.G., Williams, J.M.. (2003). The Craft of Research. University of Chicago Press. The United States of America. [38] Burnet, F.. (1935). Propagation of the Virus of Epidemic Influenza on the Developing Egg. Medical Journal of Australia 2, 687-689. [39] Burnet, F.. (1936). Influenza Virus on the Developing Egg: I. Changes Associated with the Development of an Egg-Passage Strain of Virus. British Journal of Experimental Pathology 17, 282. [40] Burnet, F.. (1940a). Influenza Virus Infections of the Chick Embryo by the Amniotic Route. I. General Character of the Infections. Australian Journal of Experimental Biology and Medical Science 18, 353-360. [41] Burnet, F.. (1940b). Influenza Virus Infections of the Chick Embryo Lung. British Journal of Experimental Pathology 21, 147. [42] Burnet, F., Barnard, J.. (1933). A Virus Disease of the Canary of the Fowl‐Pox Group. The Journal of Pathology and Bacteriology 37, 107-122. [43] Carmen, J., Andreas, M.. (2008). The Importance of SPF-Eggs in Manufacturing and Testing of Poultry Vaccines, In Lohmann information. Lohmann GmbH & Co.KG, Germany. [44] Chen, T.J., Tang, D.P.. (1987). Comparing Technical Efficiency between Import-Substitution-Oriented and Export-Oriented Foreign Firms in a Developing Economy. Journal of Development Economics 26, 277-289. [45] Chen, Z., Wang, W., Zhou, H., Suguitan, A.L., Shambaugh, C., Kim, L., Zhao, J., Kemble, G., Jin, H.. (2010). Generation of Live Attenuated Novel Influenza Virus A/California/7/09 (H1N1) Vaccines with High Yield in Embryonated Chicken Eggs. Journal of Virology 84, 44-51. [46] Chu, W.W.. (1994). Import Substitution and Export-Led Growth: A Study of Taiwan's Petrochemical Industry. World Development 22, 781-794. [47] Clements, M., Murphy, B.R.. (1986). Development and Persistence of Local and Systemic Antibody Responses in Adults Given Live Attenuated or Inactivated Influenza A Virus Vaccine. Journal of Clinical Microbiology 23, 66-72. [48] Collin, N., de Radiguès, X., the World Health Organization H1N1 Vaccine Task Force. (2009). Vaccine Production Capacity for Seasonal and Pandemic (H1N1) 2009 Influenza. Vaccine 27, 5184-5186. [49] Compans, R.W., Dimmock, N.J.. (1969). An Electron Microscopic Study of Single-Cycle Infection of Chick Embryo Fibroblasts by Influenza Virus. Virology 39, 499-515. [50] Council of Europe. (1986). European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes. Council of Europe, France. [51] Dekker, S., De Boer, I., Vermeij, I., Aarnink, A., Koerkamp, P.G.. (2011). Ecological and Economic Evaluation of Dutch Egg Production Systems. Livestock Science 139, 109-121. [52] Drummond, M.F., Sculpher, M.J., Torrance, G.W., O’Brien, B., Stoddart, G.. (2008). Methods for the Economic Evaluation of Health Care Programmes 3 Ed. Oxford University Press, England. [53] Ellison, M., Fenger, M.. (2013). Social Investment, Protection and Inequality within the New Economy and Politics of Welfare in Europe. Social Policy and Society 12, 611-624. [54] European Pharmacopoeia Commission. (2013). European Pharmacopoeia 8 Ed. Council of Europe, France. [55] Frey, S., Vesikari, T., Szymczakiewicz-Multanowska, A., Lattanzi, M., Izu, A., Groth, N., Holmes, S.. (2010). Clinical Efficacy of Cell Culture—Derived and Egg-Derived Inactivated Subunit Influenza Vaccines in Healthy Adults. Clinical Infectious Diseases 51, 997-1004. [56] Furuya, Y., Regner, M., Lobigs, M., Koskinen, A., Müllbacher, A., Alsharifi, M.. (2010). Effect of Inactivation Method on the Cross-Protective Immunity Induced by Whole Killed Influenza A Viruses and Commercial Vaccine Preparations. Journal of General Virology 91, 1450-1460. [57] Gréco, M.. (2001). Key Drivers behind the Development of Global Vaccine Market. Vaccine 19, 1606-1610. [58] Habel, K.. (1945). Cultivation of Mumps Virus in the Developing Chick Embryo and Its Application to Studies of Immunity to Mumps in Man. Public Health Reports 60, 201-212. [59] Hanley, N., Spash, C.L.. (1993). Cost-Benefit Analysis and the Environment. Edward Elgar Publishing, England. [60] Hardy, C.T., Young, S.A., Webster, R.G., Naeve, C.W., Owens, R.J.. (1995). Egg Fluids and Cells of the Chorioallantoic Membrane of Embryonated Chicken Eggs Can Select Different Variants of Influenza A (H3N2) Viruses. Virology 211, 302-306. [61] Kennedy, D.. (1981). Cost-Benefit Analysis of Entitlement Problems: A Critique. Stanford Law Review 33, 387-445. [62] Luginbuhl, R.. (2000). The Commercial Production of Specific-Pathogen-Free Eggs and Chickens: The Evolution of an Industry. Avian Diseases 40, 632-637. [63] Matthews, J.. (2006). Egg-Based Production of Influenza Vaccine: 30 Years of Commercial Experience. Bridge-Washington National Academy of Engineering 36, 17. [64] Moss, W.J., Griffin, D.E.. (2006). Global Measles Elimination. Nature Review Microbiology 4, 900-908. [65] National Research Council. (1997). Occupational Health and Safety in the Care and Use of Research Animals. The National Academies Press, the United States of America. [66] National Research Council. (2011). Guide for the Care and Use of Laboratory Animals 8 Ed. The National Academies Press, the United States of America. [67] Organisation for Economic Co-operation and Development. (2006). Recent Development, In Cost-Benefit Analysis and the Environment. OECD Publishing, France. [68] Organisation for Economic Co-operation and Development. (2006). The Stages of a Practical Cost-benefit Analysis, In: Cost-Benefit Analysis and the Environment. OECD Publishing, France. [69] Phelan, C., Rustichini, A.. (2015). Pareto Efficiency and Identity. National Bureau of Economic Research Working Paper Series 20883. [70] Reed, S.G., Bertholet, S., Coler, R.N., Friede, M.. (2009). New Horizons in Adjuvants for Vaccine Development. Trends in Immunology 30, 23-32. [71] Reisinger, K.S., Block, S.L., Izu, A., Groth, N., Holmes, S.J.. (2009). Subunit Influenza Vaccines Produced from Cell Culture or in Embryonated Chicken Eggs: Comparison of Safety, Reactogenicity, and Immunogenicity. Journal of Infectious Diseases 200, 849-857. [72] Rimmelzwaan, G.F., Osterhaus, A.D.. (2001). Influenza Vaccines: New Developments. Current Opinion in Pharmacology 1, 491-496. [73] Robertson, J.. (1993). Clinical Influenza Virus and the Embryonated Hen's Egg. Reviews in Medical Virology 3, 97-106. [74] Sheridan, C.. (2005). The Business of Making Vaccines. Nature Biotechnology 23, 1359-1366. [75] Subbarao, K., Klimov, A., Katz, J., Regnery, H., Lim, W., Hall, H., Perdue, M., Swayne, D., Bender, C., Huang, J.. (1998). Characterization of an Avian Influenza A (H5N1) Virus Isolated from A Child with a Fatal Respiratory Illness. Science 279, 393-396 [76] Tree, J.A., Richardson, C., Fooks, A.R., Clegg, J.C., Looby, D.. (2001). Comparison of Large-Scale Mammalian Cell Culture Systems with Egg Culture for the Production of Influenza Virus A Vaccine Strains. Vaccine 19, 3444-3450. [77] Ulmer, J.B., Valley, U., Rappuoli, R.. (2006). Vaccine Manufacturing: Challenges and Solutions. Nature Biotechnology 24, 1377-1383. [78] United States Department of Agriculture. (2012). ARS Facilities Design Standards. Animal Facility, Facilities Division, Facilities Engineering Branch AFM/ARS, the United States of America. [79] Watson, B.K., Coons, A.H.. (1954). Studies of Influenza Virus Infection in the Chick Embryo Using Fluorescent Antibody. The Journal of Experimental Medicine 99, 419-428. [80] Wolfensohn, S., Lloyd, M.. (2013). Handbook of Laboratory Animal Management and Welfare. Wiley-Blackwell, England. [81] Wood, J.M., Robertson, J.S.. (2004). From Lethal Virus to Life-Saving Vaccine: Developing Inactivated Vaccines for Pandemic Influenza. Nature Reviews Microbiology 2, 842-847. [82] World Health Organization. (2005). Recommendations for the Production and Control of Influenza Vaccines. WHO Press, Switzerland [83] Zhang, G.. (2013). Accounting Standards, Cost of Capital, Resource Allocation, and Welfare in a Large Economy. The Accounting Review 88, 1459-1488. [84] World Health Organization. (2012). GAP: Guidance on Development and Implementation of a National Deployment and Vaccination Plan for Pandemic Influenza Vaccines. WHO Press, Switzerland. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4524 | - |
| dc.description.abstract | 生醫用雞胚胎蛋生產模式根據疫苗種類、製程與實驗目的之需求不同，可分為無特定病原與傳統清淨兩種不同等級。為了解決生醫用胚胎蛋「生產規範不明」與「供需不平衡」之問題，本研究希望援引國際規範與認證標準、國內實驗動物相關準則與國內畜牧營業相關法規，並酌情產業現況以建立可規模化之生醫用雞胚胎蛋生產模式，希望提供訂定生產規範時之參考並按其建造與營運特性分類，進一步以淨現值法、情境分析法與Kaldor-Hick’s 補償原則來探討其投資與產業之經濟效益，並提出評價與決策建議。
關於整體成本特性的探討，無特定病原等級生產模式無論建造或營運成本均高於清淨等級生產模式。隨著飼養數量增加，無特定病原等級的建造成本增長性小於清淨等級，營運成本增長性則大於清淨等級。兩種方案邊際成本皆遞減，其中又以無特定病原的遞減幅度較大，直到飼養4千羽以上遞減效率最佳。除了探討不同等級生產成本，並可依據近5年國內市場研究資料假設積極投資與保守投資兩種生產規模，進而探討其20年內淨現值與回本情況。 關於投資經濟效益的評估，對決策者有利的方案由高至低分別為清淨等級積極投資模式(飼養115,051羽，年產1,700萬枚)、清淨等級保守投資規模(飼養87,981羽，年產1,300萬枚)、無特定病原等級積極投資模式(飼養8,798羽，年產130萬枚)，並分別於第6、6、12年回本，且無特定病原等級生產模式的預期未來需求量不得超過現有需求量之1.17倍，清淨等級不得大於1.44倍；而無特定病原等級保守投資模式(飼養677羽，年產10萬枚) 則造成虧損。對國內其他胚胎蛋生產業者無論任何方案皆因業務競爭而造成損失；對國產疫苗廠商有利的方案由高至低分別無特定病原等級積極投資模式、無特定病原等級保守投資規模；而清淨等級積極與保守投資規模若在目前的競爭訂價情況下則無影響。對總體產業而言，具有公眾淨效益的方案僅有無特定病原等級積極投資模式。沒有任何方案能符合帕累圖最適狀態，諸方案皆會造成部分個體之損失。 關於決策建議，為達成投資決策人與產業最大淨效益，本研究建議決策者建立稍具規模化之無特定病原等級生產模式(飼養至少3,358羽)。抑或建立較小規模生產模式，但需具備較低成本的資源取得能力或經由政府補貼方案來分散投資風險。同時建議與疫苗業者共同研議配合生產計畫，甚至透過投資關係轉嫁成本而建立自有供應鏈，以達成最有效率的生產與應用。另外，建議投資人應與國內民間既有胚胎蛋生產業者進行行銷或技術開發之合作，避免直接競爭關係。本研究也建議政府應分別於政策面、體制面與資源面給予產業協助。透過國際化規範與聯盟的建立、完整公正的國家級第三方疾病檢驗單位的分工、關鍵技術的產學合作，與生獎勵補助方案與監督輔導機制等，貫徹實現我國生技疫苗產業鏈上下游的完整性、人才的培育與國際外銷策略的發展。期許在國民防疫安全的良好維護下，更能使台灣未來成為東亞、東南亞地區重要的疫苗與原料研發與供應核心。 | zh_TW |
| dc.description.abstract | Embryonic eggs can be classified into specific-pathogen free (SPF) and conventional clean (clean) grades based on vaccine types and experiment objectives. We referred to international guides, local government regulations, and industrial information to establish mass production programs of embryonic eggs for biomedical use as well as to solve the “unclear standard” and the “imbalance of supply and demand” of embryonic eggs for biomedical use. Besides providing definition and guidance for embryonic eggs production, these programs were further analyzed in terms of their cost and benefit based on their construction and operation plans. In addition, net present value, scenario analysis, and Kaldor–Hicks efficiency were used to investigate the investment and industry benefits of the programs. Furthermore, evaluations were performed and suggestions were provided by the three approaches.
The results of the analysis revealed that the clean program under active investment (115,051 chickens with 17 million eggs production per year), the clean program under conserved investment (87,981 chickens with 12 million eggs production per year), and the SPF program under active investment (8,798 chickens with 1.3 million eggs production per year) will benefit investors and be break even at years 6, 6, 12. The over-expected raising and production scales of SPF and clean programs should not exceed 1.17 and 1.44 times than the present needs. The SPF program under conserved investment (677 chickens with 0.1 million eggs production per year) may not be profitable. All the programs will lead to losses to local competitors. The SPF programs will benefit vaccine manufacturers. However, considering the development of the entire industry, the SPF program under active investment is the only solution. Every program may cause some losses to the stakeholders. We recommend the investment of the SPF program with 3,358 chickens as the basic raising scale or the smaller investment with the assessment of cheaper resources and official subsidy for the benefit of the investor and industry. Meanwhile, we suggest cooperation between investor and vaccine manufacturers through the organized production–purchase plans as well as investing relations. In addition, we suggest the co-development of sales and techniques between investor and local competitors to prevent the vicious competition. Furthermore, we recommend the government to assist the industry through its policies, systems, and resources. Through the establishment of international norms and unions, the establishment of national disease inspection units, the cooperation of techniques development, and the subsidy as well as supervision of the government, the domestic vaccine industry chain, biotechnical talents, and export strategies will be completely implemented. These efforts will ensure not only good immunization plans in the nation, but also ensure that a new prospect of being the core of vaccine supply is achieved along with its development in East and Southeast Asia. | en |
| dc.description.provenance | Made available in DSpace on 2021-05-14T17:42:59Z (GMT). No. of bitstreams: 1 ntu-104-R02629001-1.pdf: 2204858 bytes, checksum: 0c163dd03d45e5a52077459e6adee182 (MD5) Previous issue date: 2015 | en |
| dc.description.tableofcontents | 誌謝 I
摘要 II Abstract IV 目錄 VI Table VIII Figure X 第一章 緒論 1 第一節 研究背景 1 第二節 研究目的 2 第三節 研究方法 3 第四節 本文架構 4 第二章 文獻探討 6 第一節 胚胎蛋源疫苗技術 6 第二節 成本效益分析理論 7 第三節 產業相關研究文獻 11 第四節 小結 15 第三章 生醫用胚胎蛋產業現況 17 第一節 生醫用胚胎蛋介紹 17 第二節 國內供應來源 21 第三節 胚胎蛋源疫苗產業 26 第四節 小結 31 第四章 建立並探討生產模式之成本效益 33 第一節 建立決策架構 33 第二節 生產模式特性 40 第三節 生產成本 54 第四節 產出效益 64 第五節 統計與分析 69 第五章 分析並評價生產模式之成本效益 71 第一節 投資成本效益 71 第二節 利益相關人效益 79 第三節 評價與決策建議 84 第四節 限制與未來研究方向 88 第六章 結論 90 參考文獻 93 | |
| dc.language.iso | zh-TW | |
| dc.subject | 疫苗 | zh_TW |
| dc.subject | 胚胎蛋 | zh_TW |
| dc.subject | 情境分析 | zh_TW |
| dc.subject | 凈現值 | zh_TW |
| dc.subject | 成本效益 | zh_TW |
| dc.subject | Cost–benefit analysis | en |
| dc.subject | Vaccine | en |
| dc.subject | Net present value | en |
| dc.subject | Scenario analysis | en |
| dc.subject | Embryonic eggs | en |
| dc.title | 評估生醫用雞胚胎蛋生產模式之成本與效益 | zh_TW |
| dc.title | Assessment and Cost-Benefit Analysis of Embryonic
Eggs Production for Biomedical Use | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 103-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 邱智賢,黃慶原,李易達 | |
| dc.subject.keyword | 胚胎蛋,疫苗,成本效益,凈現值,情境分析, | zh_TW |
| dc.subject.keyword | Embryonic eggs,Vaccine,Cost–benefit analysis,Net present value,Scenario analysis, | en |
| dc.relation.page | 155 | |
| dc.rights.note | 同意授權(全球公開) | |
| dc.date.accepted | 2015-08-13 | |
| dc.contributor.author-college | 獸醫專業學院 | zh_TW |
| dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
| 顯示於系所單位： | 獸醫學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-104-1.pdf | 2.15 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。